62019-71-0 Usage
General Description
4,5,6,7-Tetrahydrothieno[2,3-c]pyridine, also known as THTP, is a heterocyclic compound with a pyridine ring fused to a thiophene ring. It is a clear, colorless liquid with a faint odor, and it is insoluble in water but soluble in organic solvents. THTP is used as a building block in the synthesis of various pharmaceuticals, agrochemicals, and other fine chemicals. It is also employed as a reagent in organic synthesis, particularly in the production of heterocyclic compounds. THTP has biological activity and has been investigated for its potential as a drug candidate for various therapeutic applications, including in the treatment of cancer and neurological disorders. Its structure and properties make it a versatile and valuable compound in the field of organic chemistry and drug development.
Check Digit Verification of cas no
The CAS Registry Mumber 62019-71-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,2,0,1 and 9 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 62019-71:
(7*6)+(6*2)+(5*0)+(4*1)+(3*9)+(2*7)+(1*1)=100
100 % 10 = 0
So 62019-71-0 is a valid CAS Registry Number.
62019-71-0Relevant articles and documents
Design, synthesis and evaluation of novel N-phenylbutanamide derivatives as KCNQ openers for the treatment of epilepsy
Yang, Shaoning,Lu, Dingqiang,Ouyang, Pingkai
, p. 3004 - 3008 (2018/07/31)
KCNQ (Kv7) has emerged as a validated target for the development of novel anti-epileptic drugs. In this paper, a series of novel N-phenylbutanamide derivatives were designed, synthesized and evaluated as KCNQ openers for the treatment of epilepsy. These compounds were evaluated for their KCNQ opening activity in vitro and in vivo. Several compounds were found to be potent KCNQ openers. Compound 1 with favorable in vitro activity was submitted to evaluation in vivo. Results showed that compound 1 owned significant anti-convulsant activity with no adverse effects. It was also found to posses favorable pharmacokinetic profiles in rat. This research may provide novel potent compounds for the discovery of KCNQ openers in treating epilepsy.
